000 01765cam a2200349 a 4500
003 EG-GiCUC
005 20250223030901.0
008 131102s2013 ua f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.33.Ph.D.2013.Ha.F
100 0 _aHaitham Ahmed Ali Gabr
245 1 0 _aFluvastatin as an adjuvant therapy with pegylated interferon and ribavirin in the treatment of chronic hepatitis C virus /
_cHaitham Ahmed Ali Gabr ; Supervised Zakaria A. Salama , Moataz Serry Seyam , Ahmed Fouad Soliman
246 1 5 _aالفلوفاستاتين كعقار مساعد لعقاري الانترفيرون طويل المفعول و الريبافيرين فى علاج الالتهاب الكبدى الوبائى الفيروسي (سى) المزمن
260 _aCairo :
_bHaitham Ahmed Ali Gabr ,
_c2013
300 _a288 P. ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine
520 _aIt could be argued that statins, besides a weak direct antiviral effect, may enhance HCV infectivity of hepatocytes through the decrease in circulating LDL levels and the up-regulation of LDL receptors. This effect of statins might counterbalance the antiviral activity described in the replicon models
530 _aIssued also as CD
653 4 _aFluvastatin
653 4 _aStatins and HCV
653 4 _aTreatment of HCV
700 0 _aAhmed Fouad Soliman ,
_eSupervisor
700 0 _aMoataz Serry Seyam ,
_eSupervisor
700 0 _aZakaria Abdellateef Salama ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c43962
_d43962